Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company specializing in cancer therapies through GSK-3β inhibition, has announced its participation in two major investor conferences in February 2025.

The company's President & CEO, Daniel Schmitt, will attend the BIO CEO & Investor Conference on February 10, 2025, in New York, participating in the 'IPO Class of 2024 Panel' and offering one-on-one meetings with registered attendees.

Additionally, Actuate will be present at the B. Riley Precision Oncology & Radiopharma Conference on February 28, 2025, also in New York, where management will participate in a fireside chat and hold one-on-one meetings arranged through B. Riley representatives.

CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will participate in the following upcoming investor conferences:

BIO CEO & Investor Conference
Format: "IPO Class of 2024 Panel" and one-on-one meetings
Date: February 10, 2025
Location: New York, NY

Registered conference attendees may schedule one-on-one meetings with Actuate management via the conference scheduling platform.

B. Riley Precision Oncology & Radiopharma Conference
Format: Fireside chat and one-on-one meetings
Date: February 28, 2025
Location: New York, NY

Please contact your B. Riley representative to request a one-on-one meeting with management.

About Actuate Therapeutics, Inc.

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DNA Damage Response (DDR) pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements about us, including our clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; preliminary and unpublished data may be subject to change following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities; and our ability to realize any benefits or value associated with the Orphan Medicinal Product Designation (OMPD) granted to elraglusib by the EMA for the treatment of pancreatic ductal adenocarcinoma (PDAC). In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 13, 2024 and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investor Contact

Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

FAQ

Which investor conferences will Actuate Therapeutics (ACTU) attend in February 2025?

Actuate Therapeutics will attend the BIO CEO & Investor Conference on February 10 and the B. Riley Precision Oncology & Radiopharma Conference on February 28, both in New York.

What type of presentation will ACTU give at the BIO CEO & Investor Conference 2025?

At the BIO CEO & Investor Conference, Actuate will participate in the 'IPO Class of 2024 Panel' and offer one-on-one meetings with registered attendees.

What is Actuate Therapeutics' (ACTU) main research focus?

Actuate Therapeutics focuses on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β).

How can investors meet with ACTU management at the B. Riley Conference in February 2025?

Investors can request one-on-one meetings with Actuate management by contacting their B. Riley representative.